Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors

Abstract

Cytogenetic analysis and immunophenotyping might help to select elderly patients with AML who have little benefit from current therapeutic strategies and with whom new approaches might be experimented.